Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Agios Pharmaceuticals, Inc. (AGIO : NSDQ)

• Company Description    Agios Pharmaceuticals, Inc. is a biopharmaceutical company focused on development of treatments for rare genetic metabolic disorders, a subset of orphan genetic metabolic diseases. Number of Employees: 488

• Price / Volume Information    Yesterday's Closing Price: $28.04 Daily Weekly Monthly 20 Day Moving Average: 509,428 shares Shares Outstanding: 57.92 (millions) Market Capitalization: $1,623.94 (millions) Beta: 0.77 52 Week High: $62.58 52 Week Low: $23.42 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 10.79% 3.04% 12 Week -15.80% -9.09% Year To Date -14.67% -11.39%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 88 SIDNEY STREET - CAMBRIDGE,MA 02139 USA ph: 617-649-8600 fax: - ir@agios.com http://www.agios.com

• General Corporate Information    Officers Brian Goff - ChiefExecutiveOfficer Jacqualyn A. Fouse - Chair of the Board of Directors Cecilia Jones - Chief Financial Officer T.J. Washburn - Vice President; Controller Rahul Ballal - Director Peer Information Agios Pharmaceuticals, Inc. (CORR.) Agios Pharmaceuticals, Inc. (RSPI) Agios Pharmaceuticals, Inc. (CGXP) Agios Pharmaceuticals, Inc. (BGEN) Agios Pharmaceuticals, Inc. (GTBP) Agios Pharmaceuticals, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 00847X104 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/07/25 Share - Related Items Shares Outstanding: 57.92 Most Recent Split Date: (:1) Beta: 0.77 Market Capitalization: $1,623.94 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-1.82 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-7.30 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 7.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 6.71% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/07/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.11 Price/Cash Flow: - Price / Sales: 43.85 EPS Growth vs. Year Ago Period: -6.90% vs. Previous Quarter: 10.92% Sales Growth vs. Year Ago Period: 6.56% vs. Previous Quarter: -18.68% ROE 03/31/25 - -2.75 12/31/24 - -2.51 09/30/24 - -2.93 ROA 03/31/25 - -2.52 12/31/24 - -2.26 09/30/24 - -2.58 Current Ratio 03/31/25 - 18.50 12/31/24 - 11.90 09/30/24 - 8.99 Quick Ratio 03/31/25 - 17.93 12/31/24 - 11.56 09/30/24 - 8.77 Operating Margin 03/31/25 - -98.37 12/31/24 - -78.61 09/30/24 - -85.51 Net Margin 03/31/25 - 1,798.26 12/31/24 - 1,845.92 09/30/24 - 2,051.38 Pre-Tax Margin 03/31/25 - 1,917.72 12/31/24 - 1,967.15 09/30/24 - 2,212.98 Book Value 03/31/25 - 25.32 12/31/24 - 27.02 09/30/24 - 28.52 Inventory Turnover 03/31/25 - 0.17 12/31/24 - 0.16 09/30/24 - 0.15 Debt-to-Equity 03/31/25 - 0.00 12/31/24 - 0.00 09/30/24 - 0.00 Debt-to-Capital 03/31/25 - 0.00 12/31/24 - 0.00 09/30/24 - 0.00

Powered by Zacks Investment Research ©